COVID-19 Statement

In light of the global spread of COVID-19, which has affected us all, FIDE is refocusing its priorities and will join the efforts of other organizations to do everything possible to prevent the spread of this disease, and ensure the health and wellbeing of its team members, colleagues, and the general population. In the short term, all our team are working remotely and will be unable to provide you with the usual face-to-face opportunities. However, we remain committed to doing everything we can to support our clients and ensure improved outcomes for patients. To this end, we are offering virtual training and consulting solutions that can help you adapt to evolving market scenarios.

Virtual meetings

Virtual services from FIDE

Leveraging 10 years of experience developing training and consulting solutions, we have implemented new and evolved services that will help you optimize your strategies, while navigating the challenges of operating in a “virtual world”

Hear more from a FIDE expert

Watch the COVID-19 video roundtable

In light of the recent COVID-19 pandemic, a number of unique challenges have emerged for the management of patients with psoriasis, many of whom are receiving therapies such as biologics or small molecule immunosuppressants.

In this teaser video roundtable, the first in a series of expert updates on this and other topics, the FIDE Directors discuss appropriate patient management in the current setting, based on their clinical experience, including continuing/initiating therapies, considerations for patients at increased risk of COVID-19 complications, vaccination, and the practicalities of clinical trials in an environment of social distancing.

Mission statement

FIDE delivers tailored dermatology consulting services and educational programs to the biotechnology and pharmaceutical industry, providing expert clinical perspective on how modern therapies may be developed more rationally to improve patient care

Hear more from a FIDE expert